Indian pharmaceutical companies have rapidly introduced cheaper versions of Novo Nordisk’s diabetes drug Ozempic and weight-loss drug Wegovy following the expiration of semaglutide’s patent in India. Prices for these generics are about 70% lower than the original, with dozens of brands expected to hit the market as early as this year. Analysts predict over 40 […]Continue Reading
